Tilray, Inc. (TLRY Quick QuoteTLRY - Free Report) closed at $90.41 in the latest trading session, marking a -0.3% move from the prior day. This move lagged the S&P 500's daily gain of 1.29%. At the same time, the Dow added 1.55%, and the tech-heavy Nasdaq gained 1.27%.

Investors will be hoping for strength from TLRY as it approaches its next earnings release, which is expected to be November 27, 2018.

Investors might also notice recent changes to analyst estimates for TLRY. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 5.93% lower. TLRY is currently a Zacks Rank #4 (Sell).

The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 89, which puts it in the top 35% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.